Biologics, research services to be main drivers of growth in FY19, says Biocon
Updated : April 30, 2018 12:59 PM IST
The biologics and research services businesses of the company grew by 47% and 45%, respectively, in the fourth quarter of the fiscal year 2018.
The company has previously guided for USD 200 million in revenue from its biologics business and USD 250 million from research services business by FY19, and are on track to achieve those.
The Bengaluru-based firm had posted 2% increase in its consolidated net profit at Rs 130 crore for the fourth quarter ended March of 2017-18.
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morning
YOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more